Navigation Links
Orexigen Resubmits Contrave New Drug Application
Date:12/11/2013

risk profile for Contrave; and the execution of the Contrave U.S. launch by Takeda; Orexigen's plans to seek a commercialization partner in territories outside of North America; and the timing of the submission of the CSR for the interim analysis. The inclusion of forward‐looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the CSR for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; the potential for the FDA to not approve Contrave even after meeting the prespecified threshold and resubmitting the NDA; the possibility that public disclosure of the results of the interim analysis would later be deemed to jeopardize the integrity of the Light Study potentially resulting in the requirement to conduct additional, costly studies; additional analysis of the interim results or new data from the continuing Light Study, including safety-related data, may produce negative or inconclusive results, or may be inconsistent with the conclusion that the interim analysis was successful; the potential that the interim analysis may not be predictive of future results in the Light Study; the potential for early termination of Orexigen's North American collaboration agreement with Takeda; the results from the interim analysis may not be sufficient to satisfy or respond to the Day 120 List of Questions from the EMA or any other data requirements of the EMA in conn
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
2. Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
3. Orexigen Announces Successful Interim Analysis of Contrave Light Study
4. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
5. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
6. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
7. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
8. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
9. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
10. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
11. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015 Unchained Labs, a ... to this year,s PEGS conference and launches the UNit ... for biologics. PEGS: The Essential Protein Engineering Summit takes ... 2015. The UNit lets drug discovery researchers ... tool out there. Its 7 applications, 144 sample a ...
(Date:5/4/2015)... BOSTON , May 4, 2015 ... appointment of Michael Williams into the ... Mr. Williams is a senior pharmaceutical executive with ... but also long and distinguished service at industry ... His expertise spans a broad range of therapeutic ...
(Date:5/4/2015)... 4, 2015 CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to treat critically-ill and ... report Q1 2015 financial results after the market ... CytoSorbents, management will host a live conference ... operational and financial progress during Q1 2015 followed ...
Breaking Medicine Technology:Unchained Labs Lets the UNit Loose 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 4CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3
... SANYO North America Corporation (SANYO) Biomedical ... (CPWS), an integrated, stand-alone solution for GMP compliant processing ... for research use, has been installed at the University ... installation of the CPWS, as well as marking SANYO,s ...
... June 8, 2011 As hospitals scramble to adopt ... federal regulations and legislation aimed at improving healthcare in ... expansion of its interactive patient engagement solution that encourages ... teams. eSUITE™ now allows hospitals to interact with patients ...
Cached Medicine Technology:SANYO Installs First Cell Processing Work Station in the United States at University of Alabama at Birmingham 2SANYO Installs First Cell Processing Work Station in the United States at University of Alabama at Birmingham 3LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 2LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 3LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 4
(Date:5/4/2015)... 2015 “ Food Cost Calculator ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... to manage and efficiently calculate food costs. , The restaurant ... fact, the industry has an estimated 1.8 trillion dollar impact ...
(Date:5/4/2015)... 2015 The Accreditation for ... first-ever congenital heart disease (CHD) standards for ... accreditation. Driven by the latest available clinical ... review of interventional procedures in pediatric patients ... “The ACE CHD Standards for PCCL Accreditation, ...
(Date:5/4/2015)... “St. Louis has long represented opportunity ... West,” so it is the perfect place for Zerorez ... Ben Litalien, Chief Development Officer for Zerorez. “We ... will provide veterans with a $10,000 discount on our ... have a number of Military Veterans in its ranks ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Sara Soulati, ... physician practice management firm in Los Angeles associated with ... the patent-pending status of The Sara Soulati Health For ... in 2010, is a lifestyle modification and disease prevention ... 2015 to the U. S. Patents and Trademarks Office ...
(Date:5/3/2015)... Barbara Crone has joined Women’s Excellence in ... of the men, women and families who seek her care, initially ... for families in the home. , “When the ... if I could complete their care with the delivery of their ... mentor Nurse Midwife, I knew it was time for me to ...
Breaking Medicine News(10 mins):Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2
... out on the best drug treatment for their disease, because ... of print in the Archives of Disease in Childhood. ... and the disease prompts up to a third of children ... , The researchers used national data to calculate the number ...
... CINCINNATI, Sept. 3 Most children in the ... Attention Deficit,Hyperactivity Disorder (ADHD) have not been diagnosed ... medications, according to the first,national ADHD prevalence study ... criteria, according to a new study conducted by ...
... appears to be associated with adolescents risk of becoming ... in their lifetimes, according to a report in the ... one of the JAMA/Archives journals. , Previous studies have ... risk of starting to smoke, according to background information ...
... the medications they need, researchers say , , MONDAY, Sept. ... children have attention-deficit/hyperactivity disorder (ADHD), but only 32 percent ... That,s the sobering conclusion of a landmark new study, ... consider the "gold standard" of diagnostic criteria -- the ...
... Stent is Featured at ... ESC Congress 2007, ... from patient subsets of a global registry support,the use of the ... Presented today by Robbert de Winter, M.D., Ph.D., at the European,Society ...
... Cam in Cambridge, famous as a haunt of students ... become the next generation of antibiotics, according to scientists ... for General Microbiologys 161st Meeting at the University of ... With antibiotics now over-prescribed for treatments of bacterial infections, ...
Cached Medicine News:Health News:Childhood asthma still inappropriately treated in the UK 2Health News:Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New 'Gold Standard' Study by Cincinnati Children's Researchers 2Health News:Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New 'Gold Standard' Study by Cincinnati Children's Researchers 3Health News:Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New 'Gold Standard' Study by Cincinnati Children's Researchers 4Health News:Teens who see more smoking in movies may have increased risk of becoming established smokers 2Health News:9% of U.S. Kids Have ADHD 2Health News:9% of U.S. Kids Have ADHD 3Health News:Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents 2Health News:New viruses to treat bacterial diseases -- 'My enemies' enemy is my friend' 2
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches....
Curved shaft with flat 4.5 mm hook. Flat serrated handle with polished finish. Overall length: 5.3 inches....
Titanium. Small "H" shaped push-pull tip. Shaft angled 45 degrees, 9 mm from tip. Round knurled handle with dull finish. Overall length: 4.8 inches. Most popular size or model....
This suture adjuster facilitates post operative suture adjustment of running sutures while decreasing the possibility of suture damage or breakage....
Medicine Products: